Skip to main navigation Skip to search Skip to main content

Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate

  • N. E. Fullerton*
  • , M. Boyd
  • , R. J. Mairs
  • , W. N. Keith
  • , O. Alderwish
  • , M. M. Brown
  • , A. Livingstone
  • , D. Kirk
  • *Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

A targeted radiotherapy/gene therapy approach for prostate cancer, using the radiopharmaceutical [131I]meta-iodobenzylguanidine ([131I]MIBG), would restrict the effects of radiotherapy to malignant cells, thereby increasing efficacy and decreasing morbidity of radiotherapy. Prostate cancer cells were transfected with a transgene encoding the noradrenaline transporter (NAT) under the control of tumour-specific telomerase promoters, enabling them to actively take up [131I]MIBG. This led to tumour-specific cell kill. This strategy has the advantage of generating a radiological bystander effect, leading to the destruction of neighbouring tumour cells that have escaped transfection. This targeted approach could be a promising tumour-specific treatment option for prostate cancer.

Original languageEnglish
Pages (from-to)355-363
Number of pages9
JournalProstate Cancer and Prostatic Diseases
Volume7
Issue number4
Early online date12 Oct 2004
DOIs
Publication statusPublished - 1 Dec 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • [I]MIBG
  • bystander effect
  • gene therapy
  • targeted radiotherapy
  • telomerase

Fingerprint

Dive into the research topics of 'Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate'. Together they form a unique fingerprint.

Cite this